MARKET

JAGX

JAGX

Jaguar Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8633
-0.0097
-1.11%
After Hours: 0.8950 +0.0317 +3.67% 16:03 01/20 EST
OPEN
0.8700
PREV CLOSE
0.8730
HIGH
0.9100
LOW
0.8590
VOLUME
603.66K
TURNOVER
--
52 WEEK HIGH
10.89
52 WEEK LOW
0.8590
MARKET CAP
40.40M
P/E (TTM)
-0.6535
1D
5D
1M
3M
1Y
5Y
Jaguar Health plans awareness activities for launch of chemo-related dog drug Canalevia
Jaguar Health (JAGX -3.9%) plans to launch educational and awareness-building activities aimed at dog owners about canine cancer and options for treating side effects of cancer therapy in dogs. The campaign
Seekingalpha · 01/13 15:19
Jaguar Health Outlines Expected 2022 Milestones
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure (SBS-IF) and
Benzinga · 01/13 13:33
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
(NASDAQ:JAGX) today provided a corporate update and outlined expected 2022 milestones."2021 was a year of progress for Jaguar Health as we advanced our key human pipeline initiatives with the presentation at December's San Antonio Breast Cancer Symposium o...
ACCESSWIRE · 01/13 13:30
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday.
Benzinga · 01/13 11:33
Why Jaguar Health Shares Are Rising
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher following a Tuesday 13G filing from Oasis Capital showing a 9.99% stake in the company. According to the filing, Oasis Capital has a passive stake of 4,604,484 shares in Jaguar Health.
Benzinga · 01/12 17:28
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing regimen for Travelan more suited for use by the military.
Benzinga · 01/12 17:00
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDAU. veterinarians, veterinary oncologists, and members of the media can click here...
ACCESSWIRE · 01/12 13:30
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 01/12 13:22
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of JAGX. Analyze the recent business situations of Jaguar Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average JAGX stock price target is 10.88 with a high estimate of 15.00 and a low estimate of 6.75.
High15.00
Average10.88
Low6.75
Current 0.8700
EPS
Actual
Estimate
-0.36-0.27-0.18-0.09
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 33
Institutional Holdings: 7.69M
% Owned: 16.43%
Shares Outstanding: 46.80M
TypeInstitutionsShares
Increased
11
1.74M
New
4
119.18K
Decreased
12
1.52M
Sold Out
10
48.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.12%
Pharmaceuticals & Medical Research
-0.75%
Key Executives
Non-Executive Chairman/Independent Director
James Bochnowski
President/Chief Executive Officer/Director
Lisa Conte
Chief Financial Officer/Chief Accounting Officer
Carol Lizak
Executive Vice President
Karen Brunke
Chief Compliance Officer/General Counsel
Jonathan Wolin
Director of Marketing
Chip Whitlow
Secretary
Steven King
Independent Director
Gregory Divis
Independent Director
John Micek
Independent Director
Jonathan Siegel
No Data
About JAGX
Jaguar Health, Inc. is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. The Company's other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.

Webull offers kinds of Jaguar Health Inc stock information, including NASDAQ:JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.